Back to results
US 2021/0330805 A1Published application
N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy
AssigneeMemorial Sloan Kettering Cancer Center
InventorsOuathek OUERFELLI, Guangbin YANG, Sarah M. CHEAL, Steve LARSON
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.
Claims25
A compound that is
- or a pharmaceutically acceptable salt and/or solvate thereof, wherein
- X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, and X20 are each independently H or a lone pair of electrons (i.e. providing an oxygen anion);
- Y1, Y2, Y3, Y4, and Y5 are each independently O or S;
- x is 1, 2, or 3;
- and
- y is 1, 2, 3, or 4.
3 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.